Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff was April 2014. Overall response occurred in 72% of ALK inhibitor naive patients and 56% of ALK inhibitor pretreated patients.

Median duration of response was 17 months in ALK inhibitor naive patients and 8.3 months in pretreated patients. Brain metastases disease control was 79% in inhibitor naive patients and 65% in ALK pretreated patients. For more detail, see below.


This entry was posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects. Bookmark the permalink.

Leave a Reply